Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.60 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5338226 | 0.92 | HPGD (0.63) | HDAC2HDAC8HDAC6NAMPTHPGD | |
| SCHEMBL254175 | 0.91 | SRC (0.69) | HDAC2HDAC8HDAC6NAMPTSRC | |
| SCHEMBL20804355 | 0.90 | HPGD (0.57) | HDAC2HDAC8HDAC6NAMPTSRC | |
| SCHEMBL11901042 | 0.88 | HDAC6 (0.70) | HDAC2HDAC8HDAC6ERCC1ERCC4 | |
| SCHEMBL14797485 | 0.86 | NAMPT (0.54) | NAMPTSRCHPGDTSHRTP53 | |
| SCHEMBL22972224 | 0.86 | HPGD (0.57) | HDAC2HDAC8HDAC6NAMPTHPGD | |
| SCHEMBL27819670 | 0.86 | NR1H4 (0.63) | HDAC2HDAC8HDAC6PPARGHPGD | |
| SCHEMBL1569176 | 0.86 | L3MBTL1 (0.68) | NAMPT | |
| SCHEMBL10194841 | 0.86 | MMP13 (0.61) | NAMPTTP53MAPTMEN1ALDH1A1 | |
| SCHEMBL22047184 | 0.85 | PPARG (0.78) | HDAC2HDAC8HDAC6ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-01 | — | — | US | disclosed |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-01 | — | — | US | disclosed |
| EP-2651888-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080221-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2007042299-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | HDAC2 785/4885HDAC8 1227/4885HDAC6 1429/4885 |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | QDPR, TBXA2R, KCNJ11 | HDAC2 1902/4885HDAC8 3477/4885HDAC6 2900/4885 |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | CMA1, TPP1, TPSAB1 | HDAC2 2629/4885HDAC8 3169/4885HDAC6 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.